Taraxerol

Taraxerol

SCHEMBL569463

CC1(C)CC[C@]2(C)CC=C3[C@]4(C)CC[C@H]5C(C)(C)[C@@H](O)CC[C@]5(C)[C@H]4CC[C@@]3(C)[C@@H]2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 9/20 1.00
USP2 O75604 2/20 0.56
TOP2A P11388 1/20 0.55
AKR1B10 O60218 3/20 0.47
AKR1B1 P15121 1/20 0.47
POLB P06746 3/20 0.46
F3 P13726 3/20 0.46
PTPN2 P17706 3/20 0.46
SIRT5 Q9NXA8 3/20 0.46
PSMB11 A5LHX3 2/20 0.46
PSMA7 O14818 2/20 0.46
PLA2G1B P04054 2/20 0.46
PTPRC P08575 2/20 0.46
PTPRF P10586 2/20 0.46
PSMB1 P20618 2/20 0.46
CES1 P23141 2/20 0.46
ACP1 P24666 2/20 0.46
PSMA1 P25786 2/20 0.46
PSMA2 P25787 2/20 0.46
PSMA3 P25788 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Taraxerol SCHEMBL14047708 1.00 PTPN1 (1.00) PTPN1USP2TOP2AAKR1B10AKR1B1
Taraxerol SCHEMBL21264264 1.00 PTPN1 (1.00) PTPN1USP2TOP2AAKR1B10AKR1B1
Taraxerol SCHEMBL15491005 1.00 PTPN1 (1.00) PTPN1USP2TOP2AAKR1B10AKR1B1
Taraxerol SCHEMBL15491002 1.00 PTPN1 (1.00) PTPN1USP2TOP2AAKR1B10AKR1B1
Taraxerol SCHEMBL569464 1.00 PTPN1 (1.00) PTPN1USP2TOP2AAKR1B10AKR1B1
SCHEMBL4202103 0.83 PTPN1 (0.71) PTPN1USP2TOP2AAKR1B10AKR1B1
SCHEMBL19473411 0.83 PTPN1 (0.71) PTPN1USP2TOP2APOLBPTPN2
SCHEMBL29759467 0.83 PTPN1 (0.71) PTPN1USP2TOP2APOLBPTPN2
Aleuritolic Acid SCHEMBL438408 0.82 PTPN1 (0.70) PTPN1USP2AKR1B10POLBF3
SCHEMBL23929102 0.81 PTPN1 (0.67) PTPN1USP2POLBPTPN2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 997 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12134787-B2 Method for increasing the yield of oxidosqualene, triterpenes and/or triterpenoids and host cell therefore FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2024-11-05 US claimed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
US-20230172945-A1 APPLICATION OF COMPOUNDS IN CONTROLLING OR KILLING MITES Guangzhou Medical University Property Operation Limited Corporation (CN) 2023-06-08 US claimed
US-20230165921-A1 USE OF DANDELION AND MONOMER COMPOUNDS THEREOF FOR KILLING MITES Guangzhou Medical University Property Operation Limited Corporation (CN) 2023-06-01 US claimed
US-11660306-B2 Treatment of Rett syndrome COLD SPRING HARBOR LABORATORY (US) 2023-05-30 US claimed
EP-4129314-A1 USE OF DANDELION AND MONOMER COMPOUNDS THEREOF FOR KILLING MITES Smilebiotek Zhuhai Limited (CN) 2023-02-08 EP claimed
EP-4122468-A1 APPLICATION OF COMPOUNDS IN CONTROLLING OR KILLING MITES Smilebiotek Zhuhai Limited (CN) 2023-01-25 EP claimed
CN-115607586-A Application of dandelion and monomer compound thereof in mite killing 珠海岐微生物科技有限公司 2023-01-17 CN claimed
EP-3197904-B1 TREATMENT OF RETT SYNDROME COLD SPRING HARBOR LABORATORY (US) 2022-08-10 EP claimed
CN-109232500-B Method for extracting multiple monomer compounds from Chinese small Ixeris 广西中医药大学 2022-07-19 CN claimed
US-8715747-B2 Biocomposition stimulant of the immune system, anti-tumor and anti-HIV PHARMABRAND S.A. (EC) 2014-05-06 US claimed
EP-2201957-B1 ANTI-AIDS, ANTI-TUMOUR, IMMUNE-SYSTEM-STIMULATING HERBAL COMPOSITION AND PRODUCTION METHOD THEREFOR PHARMABRAND S A (EC) 2013-08-07 EP claimed
US-20120156247-A1 BIOCOMPOSITION STIMULANT OF THE IMMUNE SYSTEM, ANTI-TUMOUR AND ANTI-HIV PHARMABRAND S.A. (EC) 2012-06-21 US claimed
CN-101974060-A Semisynthesis compound with antitumor activity and application thereof SHENYANG ELIVING PHARMACEUTICAL CO LTD 2011-02-16 CN claimed
EP-2201957-A1 ANTI-AIDS, ANTI-TUMOUR, IMMUNE-SYSTEM-STIMULATING HERBAL COMPOSITION AND PRODUCTION METHOD THEREFOR Pharmabrand S.A. (EC) 2010-06-30 EP claimed
WO-2009036772-A1 ANTI-AIDS, ANTI-TUMOUR, IMMUNE-SYSTEM-STIMULATING HERBAL COMPOSITION AND PRODUCTION METHOD THEREFOR PHARMABRAND S.A. (EC) 2009-03-26 WO claimed
US-20090022821-A1 COMPOSITIONS FROM WAX MYRTLE FOR THE TREATMENT OF CANCER, CARDIOVASCULAR AND INFLAMMATORY DISEASES DEV INDERJIT KUMAR 2009-01-22 US claimed
CN-1263768-C New taraxerol derivative and its prepn and use SOUTH CHINA SEA INST OCEANOLOG (CN) 2006-07-12 CN claimed
CN-1580071-A Looking-glass plant triterpene active placement, and its preparing method and use NANHAI OCEANOGRAPHY INST CHINE (CN) 2005-02-16 CN claimed
CN-1526722-A New taraxerol derivative and its prepn and use 中国科学院南海海洋研究所 2004-09-08 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230172945-A1 APPLICATION OF COMPOUNDS IN CONTROLLING OR KILLING MITES DSTN, DDT, TYR PTPN1 1490/4885USP2 1607/4885TOP2A 3164/4885
US-11660306-B2 Treatment of Rett syndrome MECP2, BDNF, NTRK2 PTPN1 4223/4885USP2 1781/4885TOP2A 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.